[Chondroitin sulfates (CS 4&6): practical applications and economic impact]

Area of Science:

• Osteoarthritis Management
• Pharmacoeconomics
• Joint Health

Context:

• Osteoarthritis (OA) of the hip and knee significantly impacts patient quality of life and healthcare costs.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for OA pain but carry risks.
• Chondroitin sulfate (CS 4&6) has demonstrated clinical efficacy in OA management.

Purpose:

• To evaluate the economic impact of CS 4&6 on NSAID prescription patterns in France.
• To assess the correct usage of CS 4&6 regarding indications, dosage, and treatment duration.
• To quantify the reduction in NSAID use and associated healthcare expenditures.

Summary:

• A medico-economic study analyzed 11,000 osteoarthritis patients' data using IMS and THALES databases.
• CS 4&6 treatment at 1200 mg/d for several weeks led to a significant reduction in NSAID prescriptions (67% cost reduction).
• NSAID quantity decreased by 63-85.3%, with nearly half of patients avoiding NSAIDs entirely; treatment costs were offset by reduced physiotherapy and gastroprotection needs.

Impact:

• CS 4&6 treatment offers a cost-effective alternative for osteoarthritis management by reducing reliance on NSAIDs.
• The findings support the clinical benefits of CS 4&6, highlighting its potential to lower overall healthcare costs associated with osteoarthritis.
• This study validates previous clinical findings and emphasizes the economic advantages of incorporating CS 4&6 into OA treatment protocols.